Gérald Marit - Concepedia

Author

Gérald Marit

Also Known As

G Erald Marit, G MARIT, G Marit, G. MARIT, G. Marit, GERALD MARIT, Gerald Marit, Gérald Marit, Gérald Marit, Marit, Gerald

332

Publications

17.6K

Citations

H-Index

105

Concepts

All Affiliations

Hôpital Cardiologique du Haut-Lévêque Centre Hospitalier Universitaire de Bordeaux Institut Paoli-Calmettes Hôpital Purpan Université de Bordeaux

About

Gérald Marit is an author at Hôpital Cardiologique du Haut-Lévêque specializing in medicine, hematology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	29	50	2.3K
2	Health Sciences	19	26	1.6K
3	Engineering	3	3	101
4	Public Health	2	2	49
5	Biomedical Engineering	1	1	35

Gérald Marit

160

Publications

16K

Citations

H-Index

Page 1

	Year	Citations
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte Bertrand Coiffier, Catherine Thiéblemont, Éric Van Den Neste, Blood	2010	1.5K
Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma Michel Attal, Valérie Lauwers‐Cancès, Gérald Marit, New England Journal of Medicine	2012	1.1K
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome Hervé Avet‐Loiseau, Michel Attal, Philippe Moreau, Blood	2007	899
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma Michel Attal, Jean‐Luc Harousseau, Serge Leyvraz, Blood	2006	667
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia Stéphane Picard, Karine Titier, Gabriel Étienne, Blood	2006	604
Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years Philippe Rousselot, Françoise Huguet, Delphine Réa, Blood	2006	528
Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial Jean‐Luc Harousseau, Michel Attal, Hervé Avet‐Loiseau, Journal of Clinical Oncology	2010	528
Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p) Hervé Avet‐Loiseau, Xavier Leleu, Murielle Roussel, Journal of Clinical Oncology	2010	419
Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma Frédéric Garban, Michel Attal, Mauricette Michallet, Blood	2006	370
Prospective Evaluation of Magnetic Resonance Imaging and [<sup>18</sup>F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study Philippe Moreau, Michel Attal, Denis Caillot, Journal of Clinical Oncology Oncologic ImagingPet-mriProspective TrialOrthopaedic SurgeryOsteoporosis	2017	310

Page 1